Welcome to the
European Biotechnology Network!
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.
The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.
Read more about our activities here.
AZ and Innate in €1.2bn immuno-oncology deal24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.The Latest Catch is brought to you by European Biotechnology News
Under the terms of the co-development and commercialisation agreement, the Marseille-based biotech will receive cash payments of up to US$1.275bn (€1.17bn) as well as double digit royalties on sales. AstraZeneca and its biologics R&D arm Medimmune gain exclusive global rights to co-develop and commercialise IPH2201 in combination with MEDI473, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. The Swedish-British pharma giant also gains access to IPH2201 in monotherapy and other combinations in certain areas.
In addition to an initial payment of US$250m (€230m), AstraZeneca will grant further regulatory and sales-related milestones of up to US$925m (€851m). AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. Innate retains the right to co-promote in Europe with a 50% profit share in the territory.
Currently in Phase II development, IPH2201 is a potential first-in-class humanised anti-NKG2A antibody. The checkpoint receptor NKG2A inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic cells.
Our Corporate Members are
European Biotechnology Network
Avenue de Tervueren 13
1040 Brussels, Belgium
Tel: +32 27 33 72 37
Join the European Biotechnology Network!
Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.